Form 4: Kymera Therapeutics Director Bruce Booth Sells Shares Under 10b5-1 Trading Plans

Director Bruce Booth, associated with Atlas Venture funds, executed multiple sales of Kymera Therapeutics (KYMR) common stock between March 11 and March 13, 2024, under pre-arranged Rule 10b5-1 trading plans.

Summary

• Bruce Booth, a director of Kymera Therapeutics, sold shares of the company's common stock between March 11 and March 13, 2024.
• The sales were executed under Rule 10b5-1 trading plans adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.
• The transactions involved multiple sales at varying prices, with weighted average prices reported for each day's transactions.
• The sales were conducted indirectly through Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., where Booth disclaims beneficial ownership except to the extent of his pecuniary interest.
• On March 11, 2024, 37,180 shares were sold at $42.77 and 5,122 shares were sold at $43.42.
• On March 11, 2024, 7,837 shares were sold at $42.77 and 1,045 shares were sold at $43.42.
• On March 12, 2024, 126,066 shares were sold at $41.94 and 8,581 shares were sold at $42.52.
• On March 12, 2024, 26,452 shares were sold at $41.94 and 1,819 shares were sold at $42.52.
• On March 13, 2024, 108,404 shares were sold at $42.19 and 6,686 shares were sold at $42.84.
• On March 13, 2024, 22,779 shares were sold at $42.19 and 1,386 shares were sold at $42.84.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating stock sales by a director. The use of a 10b5-1 plan suggests the sales were pre-planned and doesn't necessarily reflect a negative sentiment towards the company. Therefore, the sentiment is neutral.

Industry Context

Sales by directors are a common occurrence, but the use of a 10b5-1 plan suggests the sales were pre-planned and not based on current insider information. Investors often monitor such sales for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Director stock sales are a normal part of corporate governance, and the use of 10b5-1 plans is a common practice to avoid insider trading concerns.
• Comparable companies often have similar patterns of insider trading activity, with sales typically disclosed via Form 4 filings.
• The size and frequency of these sales can be compared to those of directors at peer companies to assess whether they are unusual or within the expected range.

Stakeholder Impact

• Shareholders may react to the news of director stock sales, although the pre-planned nature of the sales under a 10b5-1 plan may mitigate concerns.
• The sales do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates